
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4067600/publications.pdf Version: 2024-02-01



MANOL GARC

#	Article	IF	CITATIONS
1	Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy. Seminars in Cancer Biology, 2022, 80, 87-106.	9.6	36
2	A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma. Seminars in Cancer Biology, 2022, 86, 682-692.	9.6	30
3	Bacteria as a treasure house of secondary metabolites with anticancer potential. Seminars in Cancer Biology, 2022, 86, 998-1013.	9.6	29
4	The multidimensional role of the Wnt∫î²â€€atenin signaling pathway in human malignancies. Journal of Cellular Physiology, 2022, 237, 199-238.	4.1	53
5	Long noncoding RNAs: A novel insight in the leukemogenesis and drug resistance in acute myeloid leukemia. Journal of Cellular Physiology, 2022, 237, 450-465.	4.1	28
6	Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	23
7	Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. Seminars in Cancer Biology, 2021, 68, 258-278.	9.6	101
8	The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Medicinal Research Reviews, 2021, 41, 1291-1336.	10.5	68
9	Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacological Research, 2021, 164, 105327.	7.1	16
10	The double-edged sword of H19 lncRNA: Insights into cancer therapy. Cancer Letters, 2021, 500, 253-262.	7.2	56
11	Featuring the special issue guest editor. Cancer Letters, 2021, 505, 73-74.	7.2	0
12	Natural products and phytochemicals as potential <scp>anti‧ARS oV</scp> â€2 drugs. Phytotherapy Research, 2021, 35, 5384-5396.	5.8	39
13	LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics. Molecular Therapy - Nucleic Acids, 2021, 24, 728-742.	5.1	45
14	Mitochondria: The metabolic switch of cellular oncogenic transformation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188534.	7.4	36
15	Development and in vitro characterisation of an induced pluripotent stem cell model of ovarian cancer. International Journal of Biochemistry and Cell Biology, 2021, 138, 106051.	2.8	9
16	Emerging role of long non-coding RNA (IncRNA) in human malignancies: A unique opportunity for precision medicine. Cancer Letters, 2021, 519, 1.	7.2	12
17	Long non-coding RNAs orchestrate various molecular and cellular processes by modulating epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166240.	3.8	18
18	Biomarkers as Putative Therapeutic Targets in Colorectal Cancer. , 2021, , 123-177.		0

2

#	Article	IF	CITATIONS
19	Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers, 2021, 13, 5479.	3.7	23
20	Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. Journal of Advanced Research, 2020, 26, 83-94.	9.5	100
21	Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential. Cancers, 2020, 12, 1901.	3.7	34
22	Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188449.	7.4	52
23	The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188423.	7.4	105
24	The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. Cellular Oncology (Dordrecht), 2020, 43, 601-616.	4.4	23
25	Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways. Biomedicines, 2020, 8, 110.	3.2	48
26	Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer. Cells, 2020, 9, 1511.	4.1	60
27	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. Journal of Molecular Medicine, 2020, 98, 1069-1091.	3.9	44
28	Deciphering the Mounting Complexity of the p53 Regulatory Network in Correlation to Long Non-Coding RNAs (IncRNAs) in Ovarian Cancer. Cells, 2020, 9, 527.	4.1	38
29	The multifaceted role of reactive oxygen species in tumorigenesis. Cellular and Molecular Life Sciences, 2020, 77, 4459-4483.	5.4	280
30	Natural products and phytochemical nanoformulations targeting mitochondria in oncotherapy: an updated review on resveratrol. Bioscience Reports, 2020, 40, .	2.4	33
31	An overview of the potential anticancer properties of cardamonin. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.8	5
32	A brief overview of antitumoral actions of bruceine D. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 200-217.	0.8	7
33	Engineering anti-cancer nanovaccine based on antigen cross-presentation. Bioscience Reports, 2019, 39,	2.4	47
34	Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. Journal of Cancer, 2018, 9, 4762-4773.	2.5	25
35	Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia, 2017, 31, 1-10.	7.2	63
36	Mutational profiling of acute lymphoblastic leukemia with testicular relapse. Journal of Hematology and Oncology, 2017, 10, 65.	17.0	16

#	Article	IF	CITATIONS
37	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific Reports, 2017, 7, 9749.	3.3	32
38	Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD. Leukemia, 2017, 31, 762-766.	7.2	9
39	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Cancer Research, 2017, 77, 390-400.	0.9	77
40	Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. Journal of Hematology and Oncology, 2017, 10, 173.	17.0	25
41	Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget, 2017, 8, 7521-7532.	1.8	37
42	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	7.2	99
43	Mutational Profiling of Acute Lymphoblastic Leukemia with Testicular Relapse. Blood, 2016, 128, 2809-2809.	1.4	1
44	Potential targeted therapeutic approaches in liposarcoma. Aging, 2016, 8, 569-570.	3.1	1
45	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Blood, 2016, 128, 452-452.	1.4	0
46	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood, 2015, 126, 2491-2501.	1.4	180
47	Establishment and Characterization of Novel Human Primary and Metastatic Anaplastic Thyroid Cancer Cell Lines and Their Genomic Evolution Over a Year as a Primagraft. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 725-735.	3.6	22
48	Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation. Bioorganic and Medicinal Chemistry, 2015, 23, 6157-6165.	3.0	100
49	LNK (SH2B3): paradoxical effects in ovarian cancer. Oncogene, 2015, 34, 1463-1474.	5.9	21
50	Genomic landscape of liposarcoma. Oncotarget, 2015, 6, 42429-42444.	1.8	94
51	Synthesis and Characterization of Novel 2-Amino-Chromene-Nitriles that Target Bcl-2 in Acute Myeloid Leukemia Cell Lines. PLoS ONE, 2014, 9, e107118.	2.5	54
52	Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 467-473.	21.4	523
53	Laminin-5Î <sup>3</sup> -2 (LAMC2) Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Progression, Migration, and Invasion by Modulating Signaling of EGFR. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E62-E72.	3.6	60
54	LAMC2 as a therapeutic target for cancers. Expert Opinion on Therapeutic Targets, 2014, 18, 979-982.	3.4	54

#	Article	IF	CITATIONS
55	Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget, 2014, 5, 4881-4894.	1.8	77
56	SOX7 is down-regulated in lung cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 17.	8.6	56
57	Sperm Associated Antigen 9 Plays an Important Role in Bladder Transitional Cell Carcinoma. PLoS ONE, 2013, 8, e81348.	2.5	32
58	Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and Tumorigenicity. American Journal of Pathology, 2011, 178, 1009-1020.	3.8	76
59	Germ cellâ€specific heat shock protein 70â€2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells. Cancer, 2010, 116, 3785-3796.	4.1	48
60	Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leukemia Research, 2010, 34, 858-863.	0.8	20
61	Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. European Journal of Cancer, 2010, 46, 207-215.	2.8	70
62	Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 630-639.	2.5	75
63	Sperm-Associated Antigen 9: A Novel Diagnostic Marker for Thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4613-4618.	3.6	45
64	Spermâ€associated antigen 9 is a biomarker for early cervical carcinoma. Cancer, 2009, 115, 2671-2683.	4.1	56
65	Small interfering RNAâ€mediated downâ€regulation of <i>SPAG9</i> inhibits cervical tumor growth. Cancer, 2009, 115, 5688-5699.	4.1	27
66	Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell Carcinoma. Cancer Research, 2008, 68, 8240-8248.	0.9	72
67	Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 1421-1428.	7.0	66
68	Small interference RNA-mediated knockdown of sperm associated antigen 9 having structural homology with c-Jun N-terminal kinase-interacting protein. Biochemical and Biophysical Research Communications, 2006, 340, 158-164.	2.1	11
69	Characterization of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9). Vaccine, 2006, 24, 3695-3703.	3.8	23
70	Immunogenicity study of recombinant human sperm-associated antigen 9 in bonnet macaque (Macaca) Tj ETQ	q0 0.0 rgB⁻ 0.9	Г /Qyerlock 10
71	Immunogenicity and contraceptive potential of recombinant human sperm associated antigen (SPAG9). Journal of Reproductive Immunology, 2005, 67, 69-76.	1.9	17